Lucira Health announced it had filed for Chapter 11 bankruptcy last week just as the diagnostics company received Emergency Use Authorization from the FDA for an at-home combination COVID-19 and flu test. In the company’s…
Continue Reading
February 23, 2023 Headlines No Comments Teladoc (TDOC) Reports Q4 Loss, Tops Revenue Estimates
Teladoc Health reports a $13.7 billion loss for FY 2022, and mixed revenue and earnings results for Q4, prompting…
Top News
Teladoc Health reports Q4 results: revenue up 15%, EPS –$0.23 versus –$0.07, beating revenue expectations but falling short on earnings.
The company reported a staggering $13.7 billion loss for FY 2022, much of…
Teladoc Health stock fell Thursday after the virtual care company reported a $13.7 billion net loss, or $84.60 per share, in 2022.That compares with a net loss of $428.8 million, or $2.73 per share,…
Continue Reading
Collective Health, a health benefits management platform, has laid off 54 employees as it arranges its workforce to better align with customer needs. The company’s CEO, Ali Diab, announced the layoffs on LinkedIn, saying the employees were being let go due to a “workforce reduction,” while urging companies that may encounter those employees during the hiring process to provide them with “strong consideration.”
Collective Health acts as a third-party health benefits administrator, bringing companies’ various benefits into one platform to let employers manage their offerings while assisting employees with navigating their healthcare.
“We can confirm that as part of a restructuring of our workforce,…
Talaris Therapeutics aimed to transform solid organ transplants with a cell therapy that replaces anti-rejection drugs patients need for the rest of their lives. But after clinical trial setbacks, the biotech has decided to end two kidney transplant studies. Although a separate test of its experimental therapy is continuing in a rare autoimmune condition, Talaris has commenced a restructuring plan that it said could culminate in a merger or sale of the company.
The restructuring announced Thursday will lead to the layoff of about one-third of Talaris’s staff. As of the end of the third quarter of 2022, the Louisville, Kentucky-based biotech…
Grifols, a company that turns blood plasma into therapies for immunological disorders and other conditions, is laying off about 2,000 U.S. workers as part of a corporate restructuring projected to yield up to €400 million in annual cost savings, the biotech announced Wednesday.
The layoffs represent about 8% of the Barcelona-based company’s global workforce, but they will happen mainly in its U.S. plasma operations. That’s notable because as a company that relies on plasma, the U.S. is vital to its business. The starting point for Grifols’s therapies is blood plasma. Key to its drug-making process is fractionation, in which the protein components…
It’s a new year, and healthcare technology vendors are rolling out their latest innovations, market approvals, acquisitions and staffing shake-ups.OptumRx launched Price Edge, a tool that compares pricing for traditional generic drugs to ensure members get the lowest prescription drug prices. A suite of new tools for both patients and providers target aspects of pharmacy logistics that have been known to delay or complicate care, such as getting real-time pharmacy benefits information and obtaining prior authorizations. In October, Optum, UnitedHealth Group’s pharmacy services company, merged with data clearinghouse Change Healthcare. The U.S. Department of Justice tried to block the merger and is appealing the…
Continue Reading
